On August 17, Mosaic Biosciences, a unit of The Mosaic Company (NYSE:MOS), launched Renuvis Enzara, an enzyme-based treatment meant to speed up how fast crop residue breaks down after harvest. The launch landed less than two weeks after Mosaic reported a second-quarter net loss of $273 million, a sharp reversal from the $411 million profit it posted in the same quarter of 2025. A fertilizer giant rolling out new agronomy products while its balance sheet absorbs a loss of that size is worth pulling apart.
A Fix For A Growing Problem
Higher-yielding hybrids, wider adoption of no-till farming and more continuous corn planting have left growers with more crop residue in their fields than in years past, and that residue is becoming an operational headache. Heavy residue narrows the window for planting, forces extra tillage passes, and can cause yield losses from uneven emergence and inconsistent seed depth. Renuvis Enzara is built around endoglucanase enzyme technology that starts breaking down residue even in cold soil, down to 32 degrees Fahrenheit, well before microbial treatments would have time to colonize. The enzyme targets the structural fibers holding residue together, opening entry points for the soil’s own microbes to finish the job. For a grower, that means reaching plant-ready fields sooner and getting better seed-to-soil contact once planting starts.
Mosaic is also making moves to protect its balance sheet while the fertilizer market stays rough. The company trimmed its 2026 capital expenditure outlook to $1.2 billion from an earlier $1.25 billion, sold its Carlsbad, New Mexico, potash mine during the quarter, and lined up a $1 billion term loan to refinance and extend its short-term commercial paper. It also kept its regular dividend at $0.22 per share even as it posted a net loss, and Potash held up as the one segment with real stability, generating $278 million in adjusted EBITDA in the second quarter of 2026, essentially matching the $278 million it produced a year earlier.
Where The Losses Are Coming From
The headline numbers explain why a new product launch matters right now. Mosaic’s second-quarter revenue came in at $2.8 billion, but the company posted an operating loss of $36 million and adjusted EBITDA fell to $407 million from $566 million in the second quarter of 2025. Phosphate was the biggest drag, swinging to an operating loss of $104 million from a loss of just $8 million a year earlier, a hit tied to sulfur availability and affordability problems that raised input costs across the segment. Mosaic Fertilizantes, the company’s Brazil business, moved the other direction too, from operating earnings of $109 million a year ago to an operating loss of $41 million in the most recent quarter.
The cash side tells a similar story. Cash flow from operations dropped to $167 million from $610 million a year earlier, a decline the company attributed to lower adjusted EBITDA and the timing of customer prepayments in Brazil. Free cash flow was negative $153 million for the quarter, compared with a positive $305 million in the second quarter of 2025, reflecting how capital spending landed during the period.
What The Market Is Pricing In
The number of hedge funds holding Mosaic slipped from 51 to 50 between the two most recent quarters, a modest pullback rather than a rush for the exits. Short interest sits at 12.06% of the float, a level that points to a real bear camp positioned against the stock. Against that, shares trade at a forward P/E of 15.92, as of September 16, a multiple that assumes earnings recover from this quarter’s depressed level rather than staying compressed. That combination is the tension investors are weighing right now.
A Company Betting On Both Ends
Mosaic is fighting this on two fronts at once: cutting costs and reshaping its portfolio in the core fertilizer business while adding new agronomy products like Renuvis Enzara on the side. For the optimistic case to play out, sulfur costs need to ease, and Brazil needs to stabilize enough for Phosphate and Mosaic Fertilizantes to stop bleeding. For the more cautious case, this quarter is a preview of how exposed Mosaic’s earnings are to input cost swings it does not fully control. Either way, the next few quarters of Potash stability and capital spending discipline will say more than any single new product launch.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
